A review of immune thrombocytopenic purpura: focus on the novel thrombopoietin agonists

Review

(2391) Views  (1278) Full article downloads

Authors: Meaghan Khan, Joseph Mikhael

Published Date March 2010 Volume 2010:1 Pages 21 - 31

DOI: http://dx.doi.org/10.2147/JBM.S6803

Meaghan Khan, Joseph Mikhael

Division of Hematology – Oncology, Scottsdale, AZ, USA

Abstract: Immune thrombocytopenic purpura (ITP) is an autoimmune disorder that is characterized by antibody-mediated platelet destruction and decreased platelet production. ITP and its treatments have been recognized to cause diminished quality of life in those afflicted with this illness on levels comparable to other chronic diseases. The disease can be self-limiting, but in adults it often is a chronic process requiring medical intervention to maintain appropriate platelet counts and to reduce bleeding events. Many patients go on to develop disease that is refractory to current interventions. Historically, the aim of treatment has been focused on reducing the amount of antibody-mediated destruction but newer therapies have centered on the decreased platelet production. Two new medications that target production of platelets have recently been USA, Food and Drug Administration (FDA) approved for the treatment of chronic relapsing ITP. Here, we provide an overview of ITP and a comprehensive review of the newest therapies aimed at the stimulation of platelet production.

Keywords: immune thrombocytopenic purpura, therapy, thrombopoietin, romiplostim, AMG 531, eltrombopag

Readers of this article also read: